Arcturus Therapeutics

Arcturus Therapeutics News & Events

Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market

November 16, 2017

Combined Company Commences Trading on the Nasdaq Global Market on November 16, 2017 under the Ticker Symbol “ARCT” Approximately $50.1 Million in Net Cash Following Closing of the Merger Ten (10) Pipeline Programs, Six (6) of Which Are Externally Funded by Pharmaceutical and Strategic Partners Arcturus Recently Signed New Strategic Collaborations with Johnson & Johnson […]

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

October 31, 2017

SAN DIEGO, Oct. 31, 2017 /PRNewswire/ — Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’s LUNAR™ lipid-mediated delivery […]

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

October 19, 2017

SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) — Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The two companies will work together to develop and commercialize […]

Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic

May 30, 2017

SAN DIEGO, May 30, 2017 /PRNewswire/ — Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that it has entered into a research agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation in which CFFT will pay up to […]